Printed From BioPortfolio.com
FDA Approves First Treatment for Nonmetastatic CRPC
12:11 EST 16 Feb 2018 | Cancer Networks
The US Food and Drug Administration (FDA) has approved the oral agent apalutamide (Erleada) for the treatment of nonmetastatic castration-resistant prostate cancer. The oral androgen-receptor inhibitor is the first FDA-approved treatment for patients with nonmetastatic castration-resistant disease and the first to be approved based on the endpoint of metastasis-free survival.
Original Article: FDA Approves First Treatment for Nonmetastatic CRPC
